The effect of treatment for gum disease (periodontitis) on the type and amount of lipids (fats) in the blood and the function of the endothelium, the thin membrane that lines the heart and blood vessels, in patients with type 2 diabetes

The impact of intensive periodontal treatment on lipid profile and endothelial function in patients with type 2 diabetes: A randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN69139365

Enrollment

290

Registered

2022-07-23

Start date

2018-03-28

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of endothelial function and serum lipid profile in patients with type 2 diabetes via periodontal treatment Oral Health

Interventions

Before treatment, patients of both groups received oral hygiene instructions. All study participants underwent Intensive Periodontal Treatment (IPT) or Control Periodontal Treatment (CPT) within 1 mon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with type 2 diabetes 2. Generalized periodontitis

Exclusion criteria

Exclusion criteria: 1. Provision of informed consent prior to initiation of any study procedures 2. Declined cognitive function and unable to make informed consent 3. Periodontal treatment within the last 12 months 4. Systemic antibiotic therapy within the last 6 months 5. Pregnancy or breastfeeding 6. Uncontrolled hypertension 7. History of heart disease or stroke which might interfere with systemic antioxidative status 8. Active smokers (>10 cigarettes/daily) were excluded

Design outcomes

Primary

Measure	Time frame
Serum lipid profile including levels of: 1. Serum total cholesterol measured by enzyme-linked immunosorbent assays (ELISA) at baseline, 3, and 6 months 2. Serum triglyceride measured by ELISA at baseline, 3, and 6 months 3. Low-density lipoprotein cholesterol measured by ELISA at baseline, 3, and 6 months 4. High-density lipoprotein cholesterol measured by ELISA at baseline, 3, and 6 months 5. Flow-mediated vasodilation (FMD) was assessed non-invasively, using the flow-mediated dilation (FMD) technique at baseline, 3, and 6 months - as an index of endothelium-dependent vasodilation	—

Measure

Time frame

Serum lipid profile including levels of: 1. Serum total cholesterol measured by enzyme-linked immunosorbent assays (ELISA) at baseline, 3, and 6 months 2. Serum triglyceride measured by ELISA at baseline, 3, and 6 months 3. Low-density lipoprotein cholesterol measured by ELISA at baseline, 3, and 6 months 4. High-density lipoprotein cholesterol measured by ELISA at baseline, 3, and 6 months 5. Flow-mediated vasodilation (FMD) was assessed non-invasively, using the flow-mediated dilation (FMD) technique at baseline, 3, and 6 months - as an index of endothelium-dependent vasodilation

—

Secondary

Measure	Time frame
1. High-sensitive C-reactive protein measured using a commercially available kit at baseline, 3, and 6 months 2. Periodontal pocket depth measured using the manual periodontal probe at baseline, 3, and 6 months 3. Clinical attachment level measured using the manual periodontal probe at baseline, 3, and 6 months	—

Countries

Albania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026